Evaluation of the biodistribution of intravenously administered CD8-mIL2 in mice demonstrated highly preferential labeling of CD8+ T cells by CD8-mIL2 in all tissues evaluated, including in subcutaneously implanted tumor (Supplementary Fig. S3A–S3C). This evidence concerns the gene CD8A and neoplasm.